1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

 
• By Emily Hayes

With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.

Rear view of businessman with suitcase looking at sunset above city

Merck & Co. Inc.'s stunning success in first-line metastatic lung cancer trials of Keytruda at the American Society of Clinical Oncology (ASCO) annual meeting set a high efficacy bar with prescribers and left its PD-1/L1 inhibitor rivals Bristol-Myers Squibb Co. and Roche on the defense.

After presentations at the ASCO meeting, held June 1-5 in Chicago, Merck's Keytruda (pembrolizumab) emerged as the clear leader in the valuable first-line non-small cell lung cancer (NSCLC) setting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.